Optimal use of bendamustine in hematologic disorders: Treatment recommendations from an international consensus panel - an update

被引:66
作者
Cheson, Bruce D. [1 ]
Brugger, Wolfram [2 ]
Damaj, Gandhi [3 ]
Dreyling, Martin [4 ]
Kahl, Brad [5 ]
Kimby, Eva [6 ]
Ogura, Michinori [7 ]
Weidmann, Eckhart [8 ]
Wendtner, Clemens-Martin [9 ]
Zinzani, Pier Luigi [10 ]
机构
[1] Georgetown Univ Hosp, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA
[2] Univ Freiburg, Schwarzwald Baar Clin, Villingen Schwenningen, Germany
[3] Univ Basse Normandie, Univ Hosp, Caen, France
[4] Univ Hosp Munich, Med Clin, Munich, Germany
[5] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA
[6] Karolinska Inst, Dept Med Huddinge, Ctr Hematol, Stockholm, Sweden
[7] Tokai Cent Hosp, Dept Hematol, Gifu, Japan
[8] Krankenhaus NW Frankfurt, Dept Hematol & Oncol, Frankfurt, Germany
[9] Univ Munich, Klinikum Schwabing Acad Teaching Hosp, Munich, Germany
[10] Univ Bologna, Inst Hematol, Bologna, Italy
关键词
CLL; NHL; multiple myeloma; Hodgkin; Bendamustine; CHRONIC LYMPHOCYTIC-LEUKEMIA; MULTICENTER PHASE-II; STEM-CELL TRANSPLANTATION; INDOLENT B-CELL; PREVIOUSLY UNTREATED PATIENTS; REFRACTORY MULTIPLE-MYELOMA; NON-HODGKINS-LYMPHOMA; MANTLE-CELL; T-CELL; OPEN-LABEL;
D O I
10.3109/10428194.2015.1099647
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bendamustine has achieved widespread international regulatory approval and is a standard agent for the treatment for chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma and multiple myeloma. Since approval, the number of indications for bendamustine has expanded to include aggressive non-Hodgkin lymphoma and Hodgkin lymphoma and novel targeted therapies, based on new bendamustine regimens/combinations, are being developed against CLL and lymphomas. In 2010, an international panel of bendamustine experts met and published a set of recommendations on the safe and effective use of bendamustine in patients suffering from hematologic disorders. In 2014, this panel met again to update these recommendations since the clarification of issues including optimal dosing and management of bendamustine-related toxicities. The aim of this report is to communicate the latest consensus on the use of bendamustine, permitting the expansion of its safe and effective administration, particularly in new combination therapies.
引用
收藏
页码:766 / 782
页数:17
相关论文
共 95 条
  • [1] Bendamustine for Hodgkin lymphoma patients failing autologous or autologous and allogeneic stem cell transplantation: a retrospective study of the Fondazione Italiana Linfomi
    Anastasia, Antonella
    Carlo-Stella, Carmelo
    Corradini, Paolo
    Salvi, Flavia
    Rusconi, Chiara
    Pulsoni, Alessandro
    Hohaus, Stefan
    Pregno, Patrizia
    Viviani, Simonetta
    Brusamolino, Ercole
    Luminari, Stefano
    Giordano, Laura
    Santoro, Armando
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (01) : 140 - 142
  • [2] [Anonymous], BLOOD
  • [3] [Anonymous], LEUK LYMPHOMA
  • [4] Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
    Berenson, James R.
    Yellin, Ori
    Bessudo, Alberto
    Boccia, Ralph V.
    Noga, Stephen J.
    Gravenor, Donald S.
    Patel-Donnelly, Dipti
    Siegel, Robert S.
    Kewalramani, Tarun
    Gorak, Edward J.
    Nassir, Youram
    Swift, Regina A.
    Mayo, Debra
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (03) : 321 - 330
  • [5] Bergmann MA, 2005, HAEMATOLOGICA, V90, P1357
  • [6] Brown JR, 2013, BLOOD, V122
  • [7] Brown JR, 2013, ASH ANN M, V122, P523
  • [8] Bendamustine in Indolent Non-Hodgkin's Lymphoma: A Practice Guide for Patient Management
    Brugger, Wolfram
    Ghielmini, Michele
    [J]. ONCOLOGIST, 2013, 18 (08) : 954 - 964
  • [9] Bendamustine and Rituximab in Relapsed and Refractory Hairy Cell Leukemia
    Burotto, Mauricio
    Stetler-Stevenson, Maryalice
    Arons, Evgeny
    Zhou, Hong
    Wilson, Wyndham
    Kreitman, Robert J.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (22) : 6313 - 6321
  • [10] Busch R., 2014, BLOOD, V124, P19, DOI [10.1182/blood.V124.21.19.19, DOI 10.1182/BLOOD.V124.21.19.19]